Cardiovascular effects of antiseizure therapies, social determinants of health on children with MS, coverage for blood-based biomarkers for Alzheimer's

Cardiovascular effects of antiseizure therapies, social determinants of health on children with MS, coverage for blood-based biomarkers for Alzheimer's

In this week's podcast, Neurology Today's editor-in-chief highlights articles on the higher risk for cardiovascular effects with certain antiseizure therapies on adults with epilepsy, the impact of social determinants of health on children with MS, and the status of coverage for blood-based tests for Alzheimer's disease.

Avsnitt(100)

Blood pressure and endovascular therapy, cutbacks in neurology CME, blood test for Alzheimer's

Blood pressure and endovascular therapy, cutbacks in neurology CME, blood test for Alzheimer's

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on blood pressure targets for stroke after endovascular therapy, changing policies on CME, and a direct-to-consumer blood test for Alzheimer's disease.

19 Okt 20234min

Football and Parkinson's, deep brain stimulation for stroke recovery, neuroprostheses for anarthric patients

Football and Parkinson's, deep brain stimulation for stroke recovery, neuroprostheses for anarthric patients

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on football and the risk for Parkinson's disease, the potential of deep brain stimulation for recovery from stroke, and neuroprostheses for patients with anarthria.

5 Okt 20234min

Medicare coverage of carotid stenting, disparities in vulnerable neuro-oncology patients, optical EMG for neuromuscular disorders.

Medicare coverage of carotid stenting, disparities in vulnerable neuro-oncology patients, optical EMG for neuromuscular disorders.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses the Medicare's proposed coverage of carotid stenting in asymptomatic patients,neuro-oncologists' perspectives on a federal initiative to target persistent poverty in vulnerable patients, and the technological promise of a new optical EMG for neuromuscular disorders.

21 Sep 20235min

Endovascular treatment and intracranial tumors; guideline on IVIG use for neuromuscular disorders, pros and cons of donanemab.

Endovascular treatment and intracranial tumors; guideline on IVIG use for neuromuscular disorders, pros and cons of donanemab.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses research that assesses the safety of endovascular treatment post-stroke for people with intracranial tumors, the AANEM guideline on IVIG use for neuromuscular disorders, and the latest data on donanemab.

7 Sep 20235min

Oral health and cognitive decline; managing first-ever sleep seizures; growth of concierge neurology.

Oral health and cognitive decline; managing first-ever sleep seizures; growth of concierge neurology.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses studies that associate poor oral health and risk for cognitive decline and how to manage first-ever sleep seizures that recur as well as the growth of concierge neurology.

17 Aug 20234min

Gene variants and MS severity, AI and EEG reads, neuroprotective agent for ischemic stroke

Gene variants and MS severity, AI and EEG reads, neuroprotective agent for ischemic stroke

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses studies that identify gene variants associated with MS severity/progression, an AI program that read EEGs accurately, and butylphthalide as a promising neuroprotective agent for ischemic stroke.

3 Aug 20235min

Antigen tolerance in mouse MS model, epileptiform activity and ICU outcomes, agent slows gliomas.

Antigen tolerance in mouse MS model, epileptiform activity and ICU outcomes, agent slows gliomas.

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses a novel therapeutic approach that induced antigen tolerance in an MS mouse model, the association between epileptiform activity and ICU outcomes, and an agent, vorasidenib, that slows low-grade gliomas.

20 Juli 20235min

Gout and risk of neurodegenereative diseases, Tenecteplase compared with warfarin, cognitive decline after heart attack

Gout and risk of neurodegenereative diseases, Tenecteplase compared with warfarin, cognitive decline after heart attack

In this week's podcast, Neurology Today's editor-in-chief discusses the association between gout and neurodegenerative diseases, tenecrteplase vs.warfarin for acute stroke, expedited cognitive decline after a heart attack.

6 Juli 20235min

Populärt inom Premium

mellan-himmel-och-jord-med-jlc
mardromsgasten
tutto-balutto
podme-dokumentar
den-som-skrattar-forlorar-podcast-2
infor-ratta
jocke-jonna-sanningen-maste-fram
filip-fredrik-svarar
en-mork-historia
hogt-i-tak-2
svenska-mordhistorier
mordpodden
rattsfallen
seriemordarpodden
daddy-issues
nemo-moter-en-van
sillypodden
bakom-galler
nhl-podden-med-bjurman-och-ekeliw
fangelsepodden